DOES SYMMETRY OF LOWER LIMB KINETICS EXIST IN SITTING AND STANDING TASKS?

This study compared sit-to-stand and stand-to-sit symmetry for total hip arthroplasty patients (n=40) and a control group (n=19). 3D kinematics and kinetics were recorded. A symmetry index was calculated for kinetics. T-tests were significant for hip and knee moments and powers, and extension sum of moments for sit-to-stand, and for hip extension moment and power for stand-to-sit. THA patients mainly rely on their nonoperated limb to perform the sit-to-stand task. There was less asymmetry during the stand-to-sit tasks, were found significant. This study underlines the presence of asymmetrical kinetics in THA patient for these tasks, and demonstrated that sit-to-stand is more sensitive to asymmetry. These results should be considered in rehabilitation programs, and consequently allow these patients to return to a more active lifestyle

IS PRINCIPAL COMPONENT ANALYSIS MORE EFFICIENT TO DETECT DIFFERENCES ON BIOMECHANICAL VARIABLES BETWEEN GROUPS?

The biomechanical analysis investigates variables such as angles, inter-segmental forces and moments at the joints. When the relevant parameters (e.g., range of motion, peak values) are selected a priori from these variables, they could not perfectly represent the information content of the original dataset. Therefore, in this study we want to validate the efficacy of the Principal Component Analysis (PCA) in overcoming the limitations of the a priori selection of the parameters. An application study is reported; the lower-limb joint mechanics between patients operated with two different surgical techniques for a total hip arthroplasty are analyzed with both the traditional analysis and the PCA. The findings from the two methods converged, but the PCA identified new sources of variability not previously detected

Enseigner au collégial, une profession à partager

Titre de l'écran-titre (visionné le 14 nov. 2007)Également disponible en format papierBibliogr

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

L’équipe de France en ordre de marche pour conquérir de nouveaux marchés

Dans un marché nucléaire international en pleine croissance où de nouveaux acteurs émergent, la filière nucléaire se met en ordre de marche autour d’un chef de file, EDF, pour apporter une offre adaptée aux besoins des pays qui développent l’énergie nucléaire. Assise sur le triptyque « qualité, innovation, sûreté », la filière porte une ambition : améliorer sa compétitivité pour remporter des appels d’offres à l’export. Pour dessiner une vision et une stratégie communes, EDF, le CEA et AREVA ont créé en mars 2016 la Plateforme France Nucléaire (PFN), une instance tripartite d’échanges sur les principaux sujets transverses de la filière en France et à l’international. Décryptage des ambitions de la filière avec les membres de cette instance: Jean-Bernard Lévy, président-directeur général d’EDF, Philippe Varin, président du conseil d’administration d’AREVA, et Daniel Verwaerde, administrateur général du CEA